SE9702533D0 - New oral formulation - Google Patents

New oral formulation

Info

Publication number
SE9702533D0
SE9702533D0 SE9702533A SE9702533A SE9702533D0 SE 9702533 D0 SE9702533 D0 SE 9702533D0 SE 9702533 A SE9702533 A SE 9702533A SE 9702533 A SE9702533 A SE 9702533A SE 9702533 D0 SE9702533 D0 SE 9702533D0
Authority
SE
Sweden
Prior art keywords
layer
oral formulation
new oral
effervescent
excipients
Prior art date
Application number
SE9702533A
Other languages
English (en)
Swedish (sv)
Inventor
Per Johan Lundberg
Mikael Thune
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9702533A priority Critical patent/SE9702533D0/xx
Publication of SE9702533D0 publication Critical patent/SE9702533D0/xx
Priority to JP50700999A priority patent/JP2002508781A/ja
Priority to DE69817587T priority patent/DE69817587T2/de
Priority to AT98931171T priority patent/ATE247952T1/de
Priority to PCT/SE1998/001209 priority patent/WO1999001112A1/en
Priority to EP98931171A priority patent/EP1014952B1/en
Priority to AU81357/98A priority patent/AU733801B2/en
Priority to US09/125,933 priority patent/US6284271B1/en
Priority to CA002294744A priority patent/CA2294744C/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
SE9702533A 1997-07-01 1997-07-01 New oral formulation SE9702533D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE9702533A SE9702533D0 (sv) 1997-07-01 1997-07-01 New oral formulation
JP50700999A JP2002508781A (ja) 1997-07-01 1998-06-22 発泡性マルチユニット製剤形
DE69817587T DE69817587T2 (de) 1997-07-01 1998-06-22 Aus einer vielzahl von kleineinheiten aufgebaute brausedosisform
AT98931171T ATE247952T1 (de) 1997-07-01 1998-06-22 Aus einer vielzahl von kleineinheiten aufgebaute brausedosisform
PCT/SE1998/001209 WO1999001112A1 (en) 1997-07-01 1998-06-22 Multiple unit effervescent dosage form
EP98931171A EP1014952B1 (en) 1997-07-01 1998-06-22 Multiple unit effervescent dosage form
AU81357/98A AU733801B2 (en) 1997-07-01 1998-06-22 Multiple unit effervescent dosage form
US09/125,933 US6284271B1 (en) 1997-07-01 1998-06-22 Multiple unit effervescent dosage form
CA002294744A CA2294744C (en) 1997-07-01 1998-06-22 Multiple unit effervescent dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702533A SE9702533D0 (sv) 1997-07-01 1997-07-01 New oral formulation

Publications (1)

Publication Number Publication Date
SE9702533D0 true SE9702533D0 (sv) 1997-07-01

Family

ID=20407594

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9702533A SE9702533D0 (sv) 1997-07-01 1997-07-01 New oral formulation

Country Status (9)

Country Link
US (1) US6284271B1 (enExample)
EP (1) EP1014952B1 (enExample)
JP (1) JP2002508781A (enExample)
AT (1) ATE247952T1 (enExample)
AU (1) AU733801B2 (enExample)
CA (1) CA2294744C (enExample)
DE (1) DE69817587T2 (enExample)
SE (1) SE9702533D0 (enExample)
WO (1) WO1999001112A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
DE19850309A1 (de) * 1998-10-30 2000-05-04 Lohmann Therapie Syst Lts Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
WO2001058424A1 (en) * 2000-02-09 2001-08-16 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Floating drug delivery composition
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
KR20040100835A (ko) 2001-02-15 2004-12-02 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
DE10111780B8 (de) * 2001-03-13 2005-02-10 Isaak Dr. Abramov Brausetablette, Pille oder Dragee, sowie das Verfahren zu ihrer Herstellung
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030190359A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
WO2004056336A2 (en) * 2002-12-20 2004-07-08 Ranbaxy Laboratories Limited Controlled release, multiple unit drug delivery systems
JP2006521366A (ja) * 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
RU2382637C2 (ru) * 2004-04-30 2010-02-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006035418A2 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
GB0427455D0 (en) * 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
KR100674622B1 (ko) * 2005-11-04 2007-01-29 재단법인 포항산업과학연구원 연료전지 발전시스템
FR2902337B1 (fr) * 2005-12-02 2010-09-17 Vacher Dominique Comprimes a liberation immediate et leur production
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
AU2007278986B2 (en) * 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
BRPI0716481A2 (pt) * 2006-09-04 2014-03-18 Panacea Biotec Ltd Tecnologia de liberação flutuante programável
GB2459393B (en) * 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
CN103120653B (zh) 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
CA2685118C (en) * 2007-04-26 2016-11-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
JP2010526054A (ja) * 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド 併用医薬組成物
HUP0700469A2 (en) * 2007-07-09 2009-04-28 Richter Gedeon Nyrt Floating pharmaceutical composition of sustained release containing metronidazol
US20120276206A1 (en) * 2008-03-28 2012-11-01 Boehringer Ingelheim International Gmbh Method for manufacturing acid pellets
JP5640079B2 (ja) 2009-05-18 2014-12-10 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 油滴含有組成物
FR2945947B1 (fr) * 2009-05-29 2011-07-29 Flamel Tech Sa Compositions pharmaceutiques flottantes a liberation controlee
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
CN102573802A (zh) 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
GB2481005B (en) * 2010-06-07 2012-08-08 Cosmetic Warriors Ltd Surfactant product comprising first and second effervescent materials
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
WO2014191806A2 (en) * 2013-05-02 2014-12-04 Effrx Pharmaceuticals Sa Effervescent formulations that deliver particles which float in the stomach
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
PT3215127T (pt) 2014-11-07 2021-02-10 Sublimity Therapeutics Ltd Composições que compreendem ciclosporina
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
KR20170003414A (ko) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
EP3167879A1 (en) * 2015-11-10 2017-05-17 Evonik Technochemie GmbH Gastric retention active delivery systems
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2025235402A1 (en) 2024-05-07 2025-11-13 Herbalife International Of America, Inc. Compositions and methods for effervescent systems with improved stability

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5512411B2 (enExample) 1974-03-12 1980-04-02
SE450087B (sv) 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US4814178A (en) 1987-07-01 1989-03-21 Sanford Bolton Floating sustained release therapeutic compositions
US5445826A (en) 1988-06-28 1995-08-29 Cibus Pharmaceutical, Inc. Delivery system containing a gel-forming dietary fiber and a drug
GB9224021D0 (en) 1992-11-16 1993-01-06 Boots Co Plc Effervescent compositions
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
EP0667149A1 (en) 1994-02-14 1995-08-16 E-PHARMA TRENTO S.p.A. Ibuprofen based effervescent composition
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
DE69419492T2 (de) 1994-03-01 2000-02-03 Gerhard Gergely Ein Brausesystem und einen Arzneiwirkstoff enthaltendes granuläres Produkt bzw. Tablette sowie Verfahren zu deren Herstellung
IE940292A1 (en) 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture
MX9600857A (es) 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare

Also Published As

Publication number Publication date
EP1014952A1 (en) 2000-07-05
EP1014952B1 (en) 2003-08-27
CA2294744C (en) 2006-10-17
CA2294744A1 (en) 1999-01-14
ATE247952T1 (de) 2003-09-15
US6284271B1 (en) 2001-09-04
WO1999001112A1 (en) 1999-01-14
AU8135798A (en) 1999-01-25
AU733801B2 (en) 2001-05-24
DE69817587D1 (de) 2003-10-02
DE69817587T2 (de) 2004-06-24
JP2002508781A (ja) 2002-03-19

Similar Documents

Publication Publication Date Title
SE9702533D0 (sv) New oral formulation
ATE216220T1 (de) Osmotische darreichungsform mit zwei mantelschichten
SE9600072D0 (sv) New oral formulation of two active ingredients II
AR002275A1 (es) Forma de dosificacion farmaceutica oral, procedimiento para la manufactura de una forma de dosificacion fija, y uso de dicha forma de dosificacionfarmaceutica oral.
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
HUP0004625A1 (hu) Az emésztőcsatorna felső szakaszának fokozott biztonságot nyújtó filmbevonatos tabletta
ATE427101T1 (de) Orales system zur verabreichung von gepulsten dosen eines arzneistoffs
DE69739165D1 (de) Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
DK0760655T3 (da) Farmaceutisk flerlags doseringsform med reguleret frigivelse
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
NO944565D0 (no) Preparat med regulert frigjörelse som inneholder et morfinsalt
IL121160A0 (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
SE9700885D0 (sv) New pharmaceutical formulation
HUP0004015A2 (hu) Három különböző, egyenként legalább egy hatóanyagot tartalmazó rétegből álló monolitikus, orális rendszer
AR008886A1 (es) Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea
FR2718020B1 (fr) Composition galénique mucoadhésive hétérofonctionnelle.
ATE304844T1 (de) Entzündungshemmende pharmazeutische formulierungen
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
IT1196190B (it) Forma farmaceutica solida orale ad azione sequenziale per la somministrazione di farmaci ad effetto collaterale ulcerogeno
BG108144A (en) New use
ES2170168T3 (es) Composiciones recubiertas entericamente de derivados de 1,5-benzodiacepina con actividad antagonista o agonista de cck.
TH22304A (th) สารเตรียมทางเภสัชกรรมแบบหลายหน่วยที่มีสารยัยยั้งปั๊มโปรตอน
ITMI922969A1 (it) Peptidi sintetici, processo per la loro preparazione, composizioni farmaceutiche che li contengono e loro impiego per la somministrazione di farmaci attraverso la barriera emato-encefalica e la retina.
JO1881B1 (en) Formula II for multi unit disc calibration